Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients

Hantke B, Harbeck N, Schmalfeldt B, Claes I, Hiller O, Luther MO, Welk A, Kuhn W, Schmitt M, Tschesche H, Muehlenweg B (2003)
BIOLOGICAL CHEMISTRY 384(8): 1247-1251.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Autor/in
; ; ; ; ; ; ; ; ; ;
Abstract / Bemerkung
Matrix metalloproteinases (MMPs) are involved in many physiological and pathophysiological processes, including tumor cell invasion and metastasis. For one member of this family, MMP-13 (collagenase-3), a new, highly specific ELISA with a sensitivity of 0.5 ng MMP-13/ml was established. The protein levels of MMP-13 in ascitic fluids of 30 patients with advanced ovarian cancer FIGO stage III (n=19) and IV (n=11) were measured with this ELISA. Using a cutoff value of 0.5 ng MMP-13/mg total protein, two patient subpopulations with short (median 16 months) and long (median 36 months) overall survival were identified. Together with other prognostic markers, determination of MMP-13 in ascitic fluid may help to identify patients at risk for early death and help to individualize adjuvant therapy.
Stichworte
collagenase-3; cancer; prognosis
Erscheinungsjahr
2003
Zeitschriftentitel
BIOLOGICAL CHEMISTRY
Band
384
Ausgabe
8
Seite(n)
1247-1251
ISSN
1431-6730
Page URI
https://pub.uni-bielefeld.de/record/1610443

Zitieren

Hantke B, Harbeck N, Schmalfeldt B, et al. Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients. BIOLOGICAL CHEMISTRY. 2003;384(8):1247-1251.
Hantke, B., Harbeck, N., Schmalfeldt, B., Claes, I., Hiller, O., Luther, M. O., Welk, A., et al. (2003). Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients. BIOLOGICAL CHEMISTRY, 384(8), 1247-1251. doi:10.1515/BC.2003.137
Hantke, B., Harbeck, N., Schmalfeldt, B., Claes, I., Hiller, O., Luther, M. O., Welk, A., Kuhn, W., Schmitt, M., Tschesche, H., et al. (2003). Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients. BIOLOGICAL CHEMISTRY 384, 1247-1251.
Hantke, B., et al., 2003. Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients. BIOLOGICAL CHEMISTRY, 384(8), p 1247-1251.
B. Hantke, et al., “Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients”, BIOLOGICAL CHEMISTRY, vol. 384, 2003, pp. 1247-1251.
Hantke, B., Harbeck, N., Schmalfeldt, B., Claes, I., Hiller, O., Luther, M.O., Welk, A., Kuhn, W., Schmitt, M., Tschesche, H., Muehlenweg, B.: Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients. BIOLOGICAL CHEMISTRY. 384, 1247-1251 (2003).
Hantke, B, Harbeck, N, Schmalfeldt, B, Claes, I, Hiller, O, Luther, MO, Welk, A, Kuhn, W, Schmitt, M, Tschesche, Harald, and Muehlenweg, B. “Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients”. BIOLOGICAL CHEMISTRY 384.8 (2003): 1247-1251.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 12974393
PubMed | Europe PMC

Suchen in

Google Scholar